Today we announced a new service agreement with Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard). Under the agreement, AGC Biologics is providing autologous production for a next-generation -therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.  

With the product currently in the pre-clinical phase, AGC Biologics will perform a process transfer and clinical manufacturing of Medigene’s product candidate at the CDMO’s Cell and Gene Center of Excellence in Milan.

“The growth of T cell immunotherapies in recent years has been astonishing. Although complex to manufacture, they offer unique therapeutic effects for patients in need,” said Luca Alberici, General Manager of AGC Biologics Milan. “Intricate cell therapy projects are not unique to our team, and we are eager to take on this challenge and help produce this cell therapy product with Medigene, a company truly focused on innovation in the field of solid tumor treatments.”

Read the full article on agcbio.com